BFRM Bioform Medical (MM)

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE TO

(Amendment No. 5)

(Rule 14d-100)

Tender Offer Statement Under Section 14(d)(1) or Section 13(e)(1)

of the Securities Exchange Act of 1934

BioForm Medical, Inc.

(Name of Subject Company (Issuer))

Vine Acquisition Corp. (Offeror)

Merz GmbH & Co. KGaA (Indirect Parent of Offeror)

(Names of Filing Persons)

COMMON STOCK, $0.01 PAR VALUE PER SHARE

(Title of Class of Securities)

09065G 107

(CUSIP Number of Class of Securities)

Matthias Vogt

Chief Financial Officer

Merz GmbH & Co. KGaA

Eckenheimer Landstrasse 100

Frankfurt am Main 60318

Germany

+49 69-1503-0

(Name, address and telephone number of person authorized to receive notices and communications on behalf of filing persons)

With a copy to:

Keith A. Flaum, Esq.

Lorenzo Borgogni, Esq.

Dewey & LeBoeuf LLP

1950 University Avenue, Suite 500

East Palo Alto, CA 92612

(650) 845-7000

CALCULATION OF FILING FEE

Check the appropriate boxes below to designate any transactions to which the statement relates:

Check the following box if the filing is a final amendment reporting the results of the tender offer:   ¨

INTRODUCTORY STATEMENT

This Amendment No. 5 (this “ Amendment ”) amends and supplements the Tender Offer Statement on Schedule TO (which, together with any amendments or supplements thereto, collectively constitute the “ Schedule TO ”) that was originally filed with the Security and Exchange Commission on January 15, 2010 by (i) Vine Acquisition Corp., a Delaware corporation (“ Acquisition Sub ”) and an indirect wholly-owned subsidiary of Merz GmbH & Co. KGaA, a limited partnership by shares formed under the laws of the Federal Republic of Germany (“ Merz ”), and (ii) Merz. The Schedule TO relates to the purchase of all of the outstanding shares of common stock, par value $0.01 per share, of BioForm Medical, Inc. (“ BioForm ”), at a purchase price of $5.45 per share, net to the seller in cash, without interest thereon and less any required withholding tax, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated January 15, 2010 (the “ Offer to Purchase ”), and in the related Letter of Transmittal (which, together with the Offer to Purchase and any amendments or supplements thereto, collectively constitute the “ Offer ”), copies of which were filed with the Schedule TO as Exhibits (a)(1) and (a)(2) thereto, respectively. This Amendment is being filed on behalf of Acquisition Sub and Merz. The information set forth in the Offer to Purchase and the related Letter of Transmittal is hereby expressly incorporated by reference in answer to Items 1 through 9 and 11 of this Amendment, and is amended and supplemented by the information specifically provided herein.

Capitalized terms used and not defined in this Amendment have the meanings assigned to such terms in the Offer to Purchase.

Item 11 of the Schedule TO is amended and supplemented by adding the following text to such Item:

The Offer expired at 12:00 midnight, New York City time, on February 12, 2010. Based on final information provided by Deutsche Bank Trust Company Americas, the Depositary for the Offer, 44,706,581 Shares (including 7,103,759 of such Shares tendered pursuant to the Offer’s guaranteed delivery procedures) were validly tendered and not withdrawn immediately prior to the expiration of the Offer. The tendered Shares represent over 94% of the shares of BioForm common stock outstanding. Acquisition Sub has accepted for payment all tendered Shares in accordance with the terms of the Offer, and Acquisition Sub will promptly pay for such Shares.

In accordance with the Merger Agreement, Acquisition Sub commenced a subsequent offering period in connection with the Offer, at 9:00 a.m., New York City time on February 16, 2010, to acquire all remaining untendered shares of BioForm common stock during the three trading day period within which Shares tendered pursuant to the guaranteed delivery procedure must be delivered to the Depositary. The subsequent offering period will expire at 12:00 midnight, New York City time, on February 18, 2010. Merz and Acquisition Sub reserve the right to extend the subsequent offering period in accordance with applicable law. Any such extension will be followed by a public announcement, which will be issued no later than 9:00 a.m., New York City time, on the next business day after the subsequent offering period was scheduled to expire. During the subsequent offering period, Acquisition Sub will accept for payment, and promptly purchase, properly tendered Shares. Holders of BioForm common stock who properly tender their Shares during the subsequent offering period will receive the same $5.45 in cash consideration per Share (without interest thereon and less any required withholding tax) that is payable to stockholders who tendered their Shares during the initial offering period. Procedures for tendering shares of BioForm common stock during the subsequent offering period are the same as during the initial offering period with two exceptions: (i) shares of BioForm common stock cannot be delivered by the guaranteed delivery procedures and (ii) pursuant to Rule 14d-7(a)(2) under the Exchange Act, shares of BioForm common stock tendered during the subsequent offering period may not be withdrawn. In addition, Shares validly tendered during the initial offering period may not be withdrawn during the subsequent offering period.

Upon acceptance for payment of, and payment by Acquisition Sub for, Shares tendered in the Offer, the Merger Agreement grants Merz the right to designate a number of individuals to BioForm’s board of directors who, following their election, will constitute at least a majority of the BioForm’s board of directors.

On February 16, 2010, Merz issued a press release announcing the results of the Offer and the commencement of the subsequent offering period. The full text of this press release is filed as Exhibit (a)(17) to the Schedule TO and is incorporated herein by reference.

2

Item 12 of the Schedule TO is hereby amended and supplemented by adding thereto the following exhibit:

3

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

Dated: February 16, 2010

4

EXHIBIT INDEX

5

6

Bioform Medical (MM) (NASDAQ:BFRM)
Historical Stock Chart
From Apr 2024 to May 2024

Bioform Medical (MM) (NASDAQ:BFRM)
Historical Stock Chart
From May 2023 to May 2024